Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism.
暂无分享,去创建一个
[1] C. Flowers,et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Gary H Lyman,et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Lara A. Kahale,et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. , 2014, The Cochrane database of systematic reviews.
[4] Mary C Politi,et al. Importance of clarifying patients’ desired role in shared decision making to match their level of engagement with their preferences , 2013, BMJ.
[5] Agnes Y. Y. Lee,et al. Treatment of cancer-associated thrombosis. , 2013, Blood.
[6] W. Olson,et al. All-cause and disease-related health care costs associated with recurrent venous thromboembolism , 2013, Thrombosis and Haemostasis.
[7] Chris Cameron,et al. Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis , 2013, BMJ.
[8] E. Akl,et al. Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. , 2013, Blood.
[9] E. Kuipers,et al. New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. , 2013, Gastroenterology.
[10] D. Coyle,et al. Estimating quality of life in acute venous thrombosis. , 2013, JAMA internal medicine.
[11] W. Ageno,et al. The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study , 2013, Journal of thrombosis and haemostasis : JTH.
[12] S. Schulman. Tossing a coin or using common sense , 2013, Journal of thrombosis and haemostasis : JTH.
[13] B. Lämmle,et al. Prospective, multicenter validation of prediction scores for major bleeding in elderly patients with venous thromboembolism , 2013, Journal of thrombosis and haemostasis : JTH.
[14] S. Goldhaber,et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. , 2013, The New England journal of medicine.
[15] G. Raskob,et al. Apixaban for extended treatment of venous thromboembolism. , 2013, The New England journal of medicine.
[16] A. Khorana,et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer , 2013, Journal of thrombosis and haemostasis : JTH.
[17] John W. Williams,et al. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. , 2012, Annals of internal medicine.
[18] D. Xavier,et al. Low-dose aspirin for preventing recurrent venous thromboembolism. , 2012, The New England journal of medicine.
[19] S. Kahn,et al. Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials , 2012, BMJ : British Medical Journal.
[20] C. Kearon,et al. Influence of hereditary or acquired thrombophilias on the treatment of venous thromboembolism , 2012, Current opinion in hematology.
[21] J. Douketis,et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH) , 2012, Journal of thrombosis and haemostasis : JTH.
[22] W. Ageno,et al. Aspirin for preventing the recurrence of venous thromboembolism. , 2012, The New England journal of medicine.
[23] J. Douketis,et al. Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep vein thrombosis: guidance from the SSC of the ISTH , 2012, Journal of Thrombosis and Haemostasis.
[24] C. Kearon,et al. A conceptual framework for two phases of anticoagulant treatment of venous thromboembolism , 2012, Journal of thrombosis and haemostasis : JTH.
[25] T. Bochenek,et al. The treatment of venous thromboembolism with low-molecular-weight heparins , 2012, Thrombosis and Haemostasis.
[26] G. Guyatt,et al. Patient values and preferences in decision making for antithrombotic therapy: a systematic review: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.
[27] Paolo Prandoni,et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.
[28] G. Guyatt,et al. ANTITHROMBOTIC THERAPY AND PREVENTION OF THROMBOSIS, 9TH ED: ACCP GUIDELINES , 2012 .
[29] P. Wells,et al. Development of a Clinical Prediction Rule for Risk Stratification of Recurrent Venous Thromboembolism in Patients With Cancer-Associated Venous Thromboembolism , 2010, Circulation.
[30] P. Wells,et al. Residual vein obstruction to predict the risk of recurrent venous thromboembolism in patients with deep vein thrombosis: a systematic review and meta‐analysis , 2011, Journal of thrombosis and haemostasis : JTH.
[31] Giancarlo Agnelli,et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials , 2011, BMJ : British Medical Journal.
[32] R. Gans,et al. Oral rivaroxaban for symptomatic venous thromboembolism. , 2011, The New England journal of medicine.
[33] Mary Cushman,et al. Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis , 2011, BMJ : British Medical Journal.
[34] J. Douketis,et al. Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient‐level meta‐analysis , 2010, Journal of thrombosis and haemostasis : JTH.
[35] A. Iorio,et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. , 2010, Archives of internal medicine.
[36] J. Douketis,et al. Patient-Level Meta-analysis: Effect of Measurement Timing, Threshold, and Patient Age on Ability of d-Dimer Testing to Assess Recurrence Risk After Unprovoked Venous Thromboembolism , 2010, Annals of Internal Medicine.
[37] H. Tilg,et al. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. , 2010, Gastroenterology.
[38] P. Wells,et al. Systematic Review: Case-Fatality Rates of Recurrent Venous Thromboembolism and Major Bleeding Events Among Patients Treated for Venous Thromboembolism , 2010, Annals of Internal Medicine.
[39] Georg Heinze,et al. Risk Assessment of Recurrence in Patients With Unprovoked Deep Vein Thrombosis or Pulmonary Embolism: The Vienna Prediction Model , 2010, Circulation.
[40] B. Cosmi,et al. Update on the predictive value of D-dimer in patients with idiopathic venous thromboembolism. , 2010, Thrombosis research.
[41] Jodi B Segal,et al. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. , 2009, JAMA.
[42] S. Kahn,et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy , 2008, Canadian Medical Association Journal.
[43] A. Kakkar. Venous thromboembolism prophylaxis and treatment in patients with cancer. , 2008, Clinical advances in hematology & oncology : H&O.
[44] D. P. Bentley,et al. Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial , 2007, BMJ : British Medical Journal.
[45] A. Iorio,et al. D-dimer testing to determine the duration of anticoagulation therapy. , 2006, The New England journal of medicine.
[46] S. Schulman,et al. Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis , 2006, The Lancet.
[47] O. Linder,et al. Post‐thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months , 2006, Journal of thrombosis and haemostasis : JTH.
[48] L. Bressollette. Eight-Year Follow-Up of Patients With Permanent Vena Cava Filters in the Prevention of Pulmonary Embolism: The PREPIC (Prévention du Risque d’Embolie Pulmonaire par Interruption Cave) Randomized Study , 2005, Circulation.
[49] Frits R Rosendaal,et al. Thrombophilia, clinical factors, and recurrent venous thrombotic events. , 2005, JAMA.
[50] T. Wakefield. Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor Ximelagatran , 2004 .
[51] Treatment of venous thromboembolism with vitamin K antagonists: patients' health state valuations and treatment preferences. , 2004, Thrombosis and haemostasis.
[52] R. Farraj. Anticoagulation period in idiopathic venous thromboembolism. How long is enough? , 2004, Saudi medical journal.
[53] J. Douketis,et al. Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor , 2004, Journal of thrombosis and haemostasis : JTH.
[54] S. Schulman,et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. , 2003, The New England journal of medicine.
[55] A. Iorio,et al. Low‐molecular‐weight heparin for the long‐term treatment of symptomatic venous thromboembolism: meta‐analysis of the randomized comparisons with oral anticoagulants , 2003, Journal of thrombosis and haemostasis : JTH.
[56] M. Gent,et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. , 2003, The New England journal of medicine.
[57] W. Ageno,et al. Extended Oral Anticoagulant Therapy after a First Episode of Pulmonary Embolism , 2003, Annals of Internal Medicine.
[58] P. Wells,et al. The outpatient bleeding risk index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism. , 2003, Archives of internal medicine.
[59] P. Ridker,et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. , 2003, The New England journal of medicine.
[60] Paolo Prandoni,et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. , 2002, Blood.
[61] P. Romano,et al. Comparison of Outcomes after Hospitalization for Deep Venous Thrombosis or Pulmonary Embolism , 2002, Thrombosis and Haemostasis.
[62] P. Monagle,et al. Post-thrombotic syndrome , 2002, Archives of disease in childhood.
[63] W. Ageno,et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. , 2001, The New England journal of medicine.
[64] I. Durieu,et al. Comparison of 3 and 6 Months of Oral Anticoagulant Therapy After a First Episode of Proximal Deep Vein Thrombosis or Pulmonary Embolism and Comparison of 6 and 12 Weeks of Therapy After Isolated Calf Deep Vein Thrombosis , 2001, Circulation.
[65] W. Ageno,et al. Warfarin Optimal Duration Italian Trial Investigators. Three months versus one year of oral anticoagulant therapy for idiopatic deep venous thrombosis. , 2001 .
[66] S. Schulman,et al. The risk of ipsilateral versus contralateral recurrent deep vein thrombosis in the leg , 2000, Journal of internal medicine.
[67] H. Eriksson,et al. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. , 2000, Archives of internal medicine.
[68] L. Melton,et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. , 2000, Archives of internal medicine.
[69] M Gent,et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. , 1999, The New England journal of medicine.
[70] L. Melton,et al. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. , 1999, Archives of internal medicine.
[71] R. White,et al. Incidence of Idiopathic Deep Venous Thrombosis and Secondary Thromboembolism among Ethnic Groups in California , 1998, Annals of Internal Medicine.
[72] O. Linder,et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. , 1997, The New England journal of medicine.
[73] M. Gent,et al. Optimal Duration of Oral Anticoagulant Therapy: A Randomized Trial Comparing Four Weeks with Three Months of Warfarin in Patients with Proximal Deep Vein Thrombosis , 1995, Thrombosis and Haemostasis.
[74] Olle Linder,et al. A Comparison of Six Weeks with Six Months of Oral Anticoagulant Therapy after a First Episode of Venous Thromboembolism , 1995 .
[75] K. Schulman,et al. Cost-effectiveness analyses. , 1995, The New England journal of medicine.
[76] Research Committee on Type 1 Diabetes of the Japan Diabetes Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism , 1992, The Lancet.
[77] Researchcommitteeofthebritish. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism*1 , 1992 .